Every pipeline review I’ve ever sat in has a moment where someone points at a deal and asks, “What happened to this one?” And the answer is almost always the same: nothing happened to it. That’s the problem. Nothing happened at all.
We talk about pipeline like it has a mortality rate. Deals are “lost.” Opportunities “die.” We run win/loss analyses as if every deal reaches a clear verdict. But look at how most B2B deals actually end, and you’ll find something less dramatic and more frustrating. They don’t lose. They just stop. The buyer goes quiet, the champion changes jobs or priorities, the evaluation gets folded into next quarter’s planning, and the deal sits in stage three until someone finally cleans up the CRM.
That distinction matters more than it sounds. A deal that dies got a decision. A deal that stalls never did. And the way you respond to each should be completely different, but in most organizations it isn’t.
We keep reaching for the wrong tool
Here’s the pattern I see over and over. Pipeline coverage looks thin, conversion between mid-funnel stages is ugly, and the instinctive response is to pour more into the top. More leads, more campaigns, more volume. It feels like action. It’s measurable. And it does absolutely nothing for the deals that are already sitting in the pipeline, stuck.
In July we made the case that the lead is the wrong finish line, that demand gen programs declare victory too early, and that the hand-off is where the thread breaks. This month we’re going one level deeper: even when the hand-off works, deals enter a stretch of the funnel where most marketing quietly checks out. The buyer is past awareness but nowhere near a decision. They’re building internal consensus, comparing options, trying to get budget attention. It’s unglamorous, it’s hard to measure, and it’s where deals go to stall.
I’ve started calling it the messy middle, because that’s exactly what it is. Not a stage in your CRM. A stretch of the buying process where the buyer’s work is mostly invisible to you, and where “did we get the lead” has long since stopped being a useful question.
Stalled deals are a different problem than missing deals
If your pipeline problem is genuinely a volume problem, more demand helps. But most teams I talk to don’t have a volume problem. They have a movement problem. The deals exist. They’re just not going anywhere.
And movement problems don’t respond to volume solutions. A stalled deal doesn’t need another top-of-funnel touch. It needs something that helps the buyer make progress inside their own organization: a reason to re-engage, a piece of ammunition their champion can carry into a budget conversation, a signal from you that arrives at the moment they’re quietly re-evaluating. Sending that buyer another gated ebook about industry trends is the marketing equivalent of revving the engine while the car is in neutral.
The uncomfortable part is that stalled deals rarely show up in anyone’s metrics. Marketing reports on leads created. Sales reports on deals won and lost. The deals in between, the ones sitting motionless for 60 or 90 days, belong to nobody’s dashboard. Which means nobody owns the fix.
What we’re doing about it
This is the question we’re spending August on: why B2B pipeline stalls, where the friction actually lives, and what marketing can do about a part of the funnel it has historically ignored.
We’ve put the full argument into a new guide, The Messy Middle: Why B2B Pipeline Stalls and What to Do About It. It covers the specific friction points that stop deals, why volume is almost never the answer, and the practical moves that create movement instead of just activity. It’s the most useful thing we’ve published this year, and I don’t say that casually.
Over the next few weeks I’ll pull apart the biggest ideas from it here, starting with the three friction points that stall nearly every pipeline. But if you’d rather skip ahead, the guide is live now.
One thought to leave you with. The next time someone in your pipeline review asks what happened to a deal, pay attention to whether the honest answer is “we lost” or “it stopped moving.” Those are two different diseases. And we’ve been prescribing for the wrong one.